Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.
Medpage Today on MSN1d
Pulled Myeloma Drug Improves Survival in TrialA significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...
A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...
Wire 3, a leading provider of high-speed fiber-optic internet, today announced the closing of a $115 million credit facility. The facility, led by Woodforest National Bank, CIBC, and JPMorgan, with ...
Blend has been positioned in the Leaders' Quadrant in AIM Research's prestigious PeMa Quadrant 2024, a comprehensive assessment of the top Generative AI service providers globally. This recognition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback